English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease Met Primary and Secondary Endpoints
Horizon Pharma plc today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent of teprotumumab patients compared to 9.5 percent of placebo patients achieved the primary endpoint of a 2 mm or more reduction in proptosis (p<0.001). Proptosis is the main cause of morbidity in TED. All secondary endpoints were also met and the safety profile was consistent with the Phase 2 study of teprotumumab in TED.
Horizon expects to submit a Biologics License Application to the U.S. Food and Drug Administration (FDA) in mid-2019. Teprotumumab has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. Detailed Phase 3 data will be submitted for publication in a peer-reviewed journal and presented at a medical congress later this year.
myBinderRelated Content
-
Gut Microbes May Play Role in Graves ’ Disease Diagnosis, Thyroid AutoimmunityThe abundance and diversity of intestina...
-
TED and Smoking: Information for PatientsHyperthyroidism is a condition where the...
-
Brian Chuck Tse, MDBrian Chuck Tse is an Assistant Professo...
-
Review of the Literature and Report of a Large Series of Patients Regarding the Association of Other Autoimmune Dise...Several studies have reported an associa...
-
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth DriversHorizon Therapeutics plc announced today...
-
Breakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...
-
Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye DiseaseMost adults with thyroid eye disease rec...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
